Skip to main content

Priapism

Priapism is a persistent penile erection lasting more than 4 hours in the absence of sexual stimulation and not relieved by ejaculation or orgasm.[1][2] It is classified by pathophysiology into three subtypes — ischemic (low-flow, veno-occlusive), non-ischemic (high-flow, arterial), and stuttering (recurrent ischemic) — each with fundamentally different management pathways. Ischemic priapism accounts for roughly 95% of cases and is a urologic emergency: beyond 4 hours, progressive ischemia, acidosis, smooth-muscle injury, and fibrosis destroy corporal tissue, and beyond 24 hours the window for medical detumescence closes and surgical intervention becomes near-mandatory.[3][4]

Management is governed by the 2021 AUA/SMSNA Guideline on Acute Ischemic Priapism and the 2022 AUA/SMSNA Guideline on Recurrent Ischemic, Sickle-Cell, and Non-Ischemic Priapism.[2][3]

Classification and Pathophysiology​

Ischemic (low-flow, veno-occlusive) priapism​

Venous outflow obstruction → blood stasis in the corpora cavernosa → progressive hypoxia, hypercapnia, acidosis, and eventually smooth-muscle necrosis and fibrosis. The corpora are rigid and painful; the glans is soft (spongiosum is not involved).[1]

Corporal blood gas:

ParameterIschemicNormal arterial
pO₂<30 mmHg>90 mmHg
pCO₂>60 mmHg<40 mmHg
pH<7.25~7.40
ColorDark, deoxygenatedBright red

Non-ischemic (high-flow, arterial) priapism​

Uncontrolled arterial inflow via an arteriocavernosal fistula, usually after blunt perineal or penile trauma (straddle injury, saddle trauma). The corpora remain oxygenated; the erection is partial and non-painful. This is not a surgical emergency — observation is first-line.[1][4]

Stuttering (recurrent ischemic) priapism​

Repeated self-limited ischemic episodes, typically <3 hours each, with intervening detumescence. Pathophysiologically ischemic and a risk factor for prolonged ischemic events.[3][5]

Molecular mechanisms (ischemic)​

  • Dysregulation of the NO–cGMP–PDE5 pathway — chronic hypoxia reduces endothelial NO and alters PDE5 set-point
  • Rho-Rho kinase pathway dysregulation
  • Adenosine accumulation — signals through A2B receptor to drive fibrosis[6]
  • Oxidative stress and reactive-oxygen-species injury
  • In sickle-cell disease: intravascular hemolysis → impaired NO bioavailability → exaggerated corpus cavernosum relaxation and sickling in the corpora during nocturnal tumescence[7][8]

Epidemiology and Etiology​

CauseComment
Sickle cell diseaseMost common identifiable cause; ~40% lifetime prevalence in men with SCD; actuarial probability of priapism by age 20 approaches 89% in homozygous SCD[5][9]
Intracavernosal injection therapyMajor cause — papaverine, phentolamine, PGE1 (alprostadil); can account for >50% of cases in some series[10]
MedicationsAntipsychotics (trazodone, chlorpromazine, risperidone), α-blockers, anticoagulants, recreational cocaine
Hematologic disordersThalassemia, polycythemia vera, multiple myeloma, CML/CLL
MalignancyMetastatic infiltration of corpora (rare but reported — bladder, prostate, renal primaries)
NeurologicSpinal cord injury (especially cervical), autonomic dysreflexia
IdiopathicSignificant proportion of adult cases
TraumaPerineal/straddle injury — non-ischemic (high-flow) priapism specifically

Initial Evaluation​

History​

  • Duration of erection (drives the urgency of intervention)
  • Preceding sexual activity, perineal trauma, recreational drugs, new medications
  • Prior priapism episodes (stuttering pattern)
  • Known sickle-cell, thalassemia, leukemia
  • Current ICI use and agent

Physical examination​

  • Ischemic: rigid corpora, soft glans, painful
  • Non-ischemic: partially tumescent, non-painful, may have perineal ecchymosis
  • Examine perineum and genitalia for evidence of recent trauma

Corporal blood gas​

The gold-standard diagnostic. A 19–21 gauge needle is placed laterally into the corpus cavernosum (avoiding the dorsal neurovascular bundle at 12 o'clock and the urethra at 6 o'clock). Aspirate; color is the first clue. Send for gas analysis. Do this before any pharmacologic intervention — it is both diagnostic and therapeutic (see aspiration below).[1][4]

Imaging​

  • Color Doppler ultrasound (CDUS) — used when blood gas is equivocal or when non-ischemic is suspected. Ischemic: absent or minimal cavernosal arterial flow. Non-ischemic: high arterial flow, often with visible arteriocavernosal fistula.[11][12]
  • MRI — useful in delayed presentations (>36–48 hours) to assess extent of cavernosal necrosis and fibrosis; informs early-implant decision
  • CT/MR angiography — defines pudendal arterial anatomy for selective embolization in non-ischemic priapism

Management — Ischemic Priapism (the Acute Emergency)​

The AUA/SMSNA algorithm is stepwise and time-pressured — each step is attempted and, if unsuccessful, escalated quickly.[2]

Step 1 — Corporal aspiration​

Laterally into the corpus cavernosum; aspirate 20–30 mL of dark blood. Aspiration alone resolves a subset of early-presentation priapism and decompresses the corpora for subsequent pharmacologic therapy.

Step 2 — Intracavernosal phenylephrine​

Phenylephrine is the α-agonist of choice due to its pure α1 selectivity (minimizing β-mediated tachycardia and hypertensive crisis).[13]

  • Dilution: 1 mg phenylephrine in 10 mL saline → 100 mcg/mL
  • Dose: 100–500 mcg per injection (1–5 mL of the dilution)
  • Frequency: every 3–5 minutes up to 1 hour of attempted resolution
  • Monitoring: continuous BP and HR; meaningful risk of hypertensive crisis, particularly in children and patients with cardiovascular disease
  • Pediatric dosing: 100 mcg doses, maximum 500 mcg total; consider cardiology monitoring

Step 3 — Repeat aspiration and irrigation​

Corporal saline irrigation combined with re-aspiration can clear residual coagulum and facilitate re-inflation of the corpora with oxygenated blood.

Step 4 — Surgical shunting (if medical management fails within 4–24 hours)​

The shunt creates a communication between the rigid corpus cavernosum and either the glans or the corpus spongiosum, allowing stasis blood to drain.

Distal shunts (attempted first):

ShuntTechnique
WinterPercutaneous large-bore biopsy needle (Tru-Cut) through the glans into the distal corpus cavernosum, creating a fistula
EbbehojStab incision with a scalpel through the glans into the distal corpus cavernosum
T-shuntT-shaped scalpel incision distally through the glans into corpus cavernosum (variant of Ebbehoj)
Al-GhorabOpen excision of a segment of distal tunica albuginea via circumcision or subcoronal incision — more durable than Winter/Ebbehoj

Proximal shunts (if distal fail):

  • Quackels (cavernosospongiosum) — perineal approach connecting corpus cavernosum to bulbar spongiosum
  • Grayhack (caverno-saphenous) — saphenous vein mobilized and anastomosed to the corpus cavernosum (largely of historical interest)

Step 5 — Distal tunneling procedures (modern addition)​

Tunneling extends the distal shunt by passing a dilator (Hegar or Mecholl) proximally through the cavernosum from the shunt site to disrupt ischemic coagulum along the entire length of the corpus. Added to the 2021 AUA/SMSNA guideline based on improving outcomes:[2]

  • Burnett snake technique — Al-Ghorab shunt + retrograde corporal tunneling with a 7/8 Hegar dilator
  • Penoscrotal decompression (PSD) — penoscrotal incision with bilateral corporotomies and proximal-to-distal tunneling; an alternative to the glans-based shunts that is gaining traction for prolonged priapism[14]

Step 6 — Early penile prosthesis implantation​

For priapism >36–48 hours (or >48 hours per some guidelines), early prosthesis implantation is the modern standard when medical management fails.[15] Rationale:

  • After 36 hours of ischemia, the prognosis for preserved natural erectile function is essentially zero (only 43% retain any function after 48+ hours, and most of those have significant dysfunction)
  • Corporal fibrosis progresses rapidly after the acute phase — implantation is substantially easier in the acute period than after 4–6 weeks of fibrosis consolidation when cavernotomes become necessary and penile shortening is inevitable
  • Early implantation preserves penile length that is otherwise lost to progressive fibrosis
  • A malleable prosthesis is often placed acutely to manage detumescence; conversion to an inflatable can follow months later if desired

Counseling is critical: the decision is between a mechanical device now with better length, or a severely fibrosed corpora requiring a difficult revision-level implantation later with significant length loss.

See penile implants — revision scenarios for the cavernotome toolkit and Carter-Trost technique used in the fibrosed corpus.

Special Considerations — Sickle Cell Disease​

The 2022 AUA/SMSNA guideline is explicit:[3]

  • Do not delay urologic intervention for exchange transfusion. Exchange transfusion does not terminate priapism faster than standard urologic management and delays effective intervention by 6+ hours — an interval during which ischemic injury progresses.
  • Simple transfusion to Hb 9–10 g/dL is reasonable before general anesthesia if surgical shunting is needed, to reduce sickling risk intraoperatively.
  • ASPEN syndrome (association of sickle cell, priapism, exchange, and neurologic events) has been described after rapid exchange transfusion — another argument against reflexive exchange.

Chronic prevention in SCD​

After an acute episode resolves, prevention of recurrence is the main goal:

  • Hydroxyurea — standard-of-care SCD therapy reduces priapism episode frequency
  • Scheduled monthly transfusion programs in selected patients
  • Pseudoephedrine at bedtime (limited evidence)
  • PDE5 inhibitors — low-dose daily sildenafil has been used with the paradoxical rationale of restoring PDE5 regulatory tone; evidence is limited but mechanism is biologically plausible[5]
  • GnRH analogues / antiandrogens — effective but with significant side-effect profiles; reserved for refractory cases

Management — Non-Ischemic (High-Flow) Priapism​

Not an emergency. Management pathway:[1][3]

  1. Observation + conservative measures — ice packs, compression, avoidance of stimulation
  2. ~60% of high-flow priapism resolves spontaneously over weeks
  3. Selective arterial embolization — if the patient desires treatment or conservative measures fail
    • Autologous clot embolization (temporary, resorbable) — preferred first-line; high success rate (~90%) with preservation of erectile function
    • Non-absorbable agents (coils, gelfoam) — higher ED risk
  4. Surgical ligation — rarely needed; reserved for embolization failures

Management — Stuttering / Recurrent Ischemic Priapism​

Acute episode: treat exactly as acute ischemic priapism (aspiration + phenylephrine).

Preventive strategies (the 2022 AUA/SMSNA guideline frames these as "may offer" options given limited evidence):[3]

  • At-home phenylephrine self-injection — for episodes not yet meeting 4-hour threshold; patient must be thoroughly trained and aware of hypertensive-crisis risk
  • Daily low-dose PDE5 inhibitor (sildenafil 25–50 mg) — paradoxical but biologically plausible mechanism
  • α-agonist agents (pseudoephedrine, etilefrine where available)
  • Ketoconazole — antiandrogenic mechanism; occasionally tried
  • GnRH analogues / antiandrogens — effective but poorly tolerated
  • Hydroxyurea / chronic transfusion for SCD-associated stuttering

Outcomes​

Duration is the dominant predictor of ED​

DurationRisk of ED
<12 hoursLow
12–24 hoursModerate
24–36 hoursHigh
>36 hoursOR 61.3 for ED[10]
>48 hoursOnly ~43% retain any erectile function; most of those with significant dysfunction[16]

Other predictors​

  • Complete detumescence at the end of intervention is the strongest short-term predictor of recovery[16]
  • Degree of fibrosis on MRI — heterogeneous low-signal areas from hemosiderin and fibrosis correlate with ED severity
  • Medical management alone achieves complete detumescence in ~78% of acute ischemic priapism cases[17]
  • Surgical shunting is required in ~10% of cases overall; lower in SCD (2.2%) than non-SCD ischemic (15.2%) etiologies[17]

Long-term complications​

  • Erectile dysfunction — the dominant long-term morbidity
  • Penile fibrosis — progressive, adenosine-A2B-driven; detected in 57% of patients with prolonged priapism[6][16]
  • Penile shortening — especially with delayed prosthesis implantation
  • Acquired penile curvature
  • Psychological distress and relationship-impacting sexual dysfunction[5]

Prolonged Priapism (≥ 24 hours) — the Operative Window​

Prolonged ischemic priapism is a categorically different problem. After 24 hours, aspiration and phenylephrine rarely achieve detumescence, and the question becomes which surgical strategy rather than whether to operate.[4][14]

Distal shunts alone have limited durability in prolonged cases because the ischemic coagulum spans the entire corporal length. Tunneling procedures — Burnett snake, penoscrotal decompression — allow more extensive disruption of this coagulum and are increasingly preferred for the 24–72-hour window.

For priapism >36–48 hours, acute prosthesis implantation is on the menu of first-line options. The logic is simple: the corpus cavernosum will fibrose regardless of what shunt is performed; implanting a malleable device during the acute phase preserves length and avoids a far more technically demanding implant 4–6 weeks later through densely fibrotic corpora.[15]

Videos​

Priapism — technique demonstration
Ischemic priapism management
Priapism management — operative video
Surgical approach and shunt technique

External video references:

  • Penoscrotal decompression of refractory ischemic priapism — surgical technique — Videos in Sexual Medicine (vjsm.info): Residents Corner
  • Penoscrotal decompression — a better method for priapism management — Videos in Sexual Medicine (vjsm.info): Full video

See Also​

References​

1. Pang KH, Alnajjar HM, Lal A, Muneer A. An update on mechanisms and treatment options for priapism. Nat Rev Urol. 2025. doi:10.1038/s41585-025-01069-9

2. Bivalacqua TJ, Allen BK, Brock G, et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021;206(5):1114–1121. doi:10.1097/JU.0000000000002236

3. Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline. J Urol. 2022;208(1):43–52. doi:10.1097/JU.0000000000002767

4. Ericson C, Baird B, Broderick GA. Management of priapism: 2021 update. Urol Clin North Am. 2021;48(4):565–576. doi:10.1016/j.ucl.2021.07.003

5. Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2022;2022(1):450–458. doi:10.1182/hematology.2022000380

6. Wen J, Jiang X, Dai Y, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 2010;24(3):740–9. doi:10.1096/fj.09-144147

7. Pereira DA, Calmasini FB, Costa FF, Burnett AL, Silva FH. Nitric oxide resistance in priapism associated with sickle cell disease: mechanisms, therapeutic challenges, and future directions. J Pharmacol Exp Ther. 2024;390(2):203–212. doi:10.1124/jpet.123.001962

8. Iacopucci APM, da Silva Pereira P, Pereira DA, et al. Intravascular hemolysis leads to exaggerated corpus cavernosum relaxation: implication for priapism in sickle cell disease. FASEB J. 2022;36(10):e22535. doi:10.1096/fj.202200867R

9. Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2020;4:CD004198. doi:10.1002/14651858.CD004198.pub4

10. Borrell JA, Bettencourt A, Furtado TP, et al. Risk factors, diagnosis, and long-term erectile dysfunction outcomes in priapism: a retrospective analysis of 186 cases from a single institution. Int J Impot Res. 2026;38(1):23–29. doi:10.1038/s41443-025-01076-9

11. von Stempel C, Walkden M, Kirkham A. Review of the role of imaging in the diagnosis of priapism. Int J Impot Res. 2024. doi:10.1038/s41443-024-00928-0

12. McHugh K, Gibbons RC. Point-of-care ultrasound diagnosis of high flow priapism. J Emerg Med. 2022;62(2):207–209. doi:10.1016/j.jemermed.2021.07.037

13. Graham BA, Abdulla W, Jack C, Mitchell RA, Hellstrom WJG. An overview of emergency pharmacotherapy for priapism. Expert Opin Pharmacother. 2022;23(12):1371–1380. doi:10.1080/14656566.2022.2099271

14. Lumbiganon S, Moukhtar Hammad MA, Azad B, Yafi FA. A narrative review of initial treatment for ischemic priapism. Int J Impot Res. 2024. doi:10.1038/s41443-024-00951-1

15. Yassin M, Chen R, Ager M, Desouky E, Minhas S. Penile implants in low flow priapism. Int J Impot Res. 2023;35(7):651–663. doi:10.1038/s41443-023-00787-1

16. El-Bahnasawy MS, Dawood A, Farouk A. Low-flow priapism: risk factors for erectile dysfunction. BJU Int. 2002;89(3):285–90. doi:10.1046/j.1464-4096.2001.01510.x

17. Masterson TA, Parmar M, Tradewell MB, et al. Using artificial intelligence to predict surgical shunts in men with ischemic priapism. J Urol. 2020;204(5):1033–1038. doi:10.1097/JU.0000000000001183